Management boasts their materials are in 99 percent of global chips while segment earnings dropped 9 percent.
Thesis: Merck is a diversified chemical conglomerate masquerading as an AI semiconductor play. Their materials are essential consumables but lack pricing power against dominant foundries. The high single-digit growth in semiconductor materials is completely absorbed by structural margin compression and legacy division collapse. You are buying a generic pharma cliff offset by commodity fab chemicals.
Verdict: AVOID — Conviction: HIGH
Catalyst: The stabilization of the DS&S business in 2026. Management claims this will return the Electronics segment to overall growth.
Key Risk: Generic entry for Mavenclad in the U.S. starting March 2026 outpaces the revenue replacement from the SpringWorks acquisition and Pergoveris.
The Tell: The CFO blamed the 9 percent Electronics EBITDA pre decline on onetime adjustments reported in the second quarter of 2025 without detailing how structural unit economics have improved since.
Friction Level: HIGH_FRICTION — The bull sees the 99 percent chip exposure and Taiwan megasite as critical bottleneck removal. The bear sees a commodity chemical supplier following TSMC with zero pricing power.
Report not found
The report data is no longer available. Please return to the archive.